Antitumor immunotherapeutic effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice

树突状细胞与肝癌细胞融合免疫小鼠的抗肿瘤免疫治疗作用

• 批准号: 14570443
• 负责人: SATO Koji
• 金额: $ 1.86万
• 依托单位: Yamagata University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570443/
• 关键词: Hepatocellular carcinoma; Pervention; Cancer vaccine; Dendritic cell; Immunotherapy; 肝細胞癌; 癌ワクチン療法

The long-term prognosis after treatment of hepatocellular carcinoma (HCC) remains poor because of high rate of tumor recurrence. Immunotherapy for cancer is attractive. Uncharacterized and mutated antigens can be targeted with whole tumor cell or tumor lysate-based immunization strategies.Our study was to investigate the antitumor effects of immunization with fusions of dendritic cells (DCs) and HCC cells against HCC tumors transplanted to mice.Fusion cells of DCs and tumor cells were prepaired with polyethylene glycol. To study the antitumor immune effects, fusions were subcutaneously injected into mice. The CTL activity was assumed by the LDH method. Mice were followed for survival and tumor size.Immunization of mice with fusions induced protective immunity against tumor challenge. Tumor antigen-pulsed DCs effectively suppressed the growth of HCC in mice. After treatment with fusions, tumor size decreased and the survival time of tumor-bearing mice was extended.Our study demonstrated that the fusion cells of DCs and tumor cells could induce effective antitumor immune responses and may be used in HCC treatment and prevention of recurrence of HCC.

由于肿瘤复发率高，肝细胞癌（HCC）治疗后的长期预后仍然很差。癌症的免疫疗法很有吸引力。未表征和突变的抗原可以用整个肿瘤细胞或基于肿瘤的裂解物免疫策略来靶向。 DC和肿瘤细胞用聚乙烯乙二醇预启动。为了研究抗肿瘤的免疫作用，将融合物皮下注入小鼠。通过LDH方法假设CTL活性。遵循小鼠的生存和肿瘤大小。融合诱导的保护性免疫对肿瘤挑战的诱导免疫。肿瘤抗原脉冲DC有效地抑制了小鼠HCC的生长。用融合治疗后，肿瘤大小减少并扩展了耐肿瘤小鼠的存活时间。 HCC。